Cancer Treatment Reviews
Volume 29, Issue 3 , Pages 219-221 , June 2003

Conformal radiotherapy with dose escalation appears safe and effective in localised prostate cancer: Abstracted from: Brundage M, Lukka H, Crook J, et al. The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 low or intermediate risk prostate cancer—a systematic review. Radiother Oncol 2002; 64: 239–50.

  • Eric M Horwitz, MD

      Affiliations

    • Corresponding Author InformationCorrespondence to: Eric M. Horwitz, MD, Fox Chase Cancer Center, Department of Radiation Oncology, 7701 Burholme Avenue, Philadelphia, PA 19111, USA. Tel.: +1-215-728-2995; fax: +1-215-214-1629

References 

  1. Vicini FA, Horwitz EM, Gonzalez J, et al.  Treatment options for localized prostate cancer based upon pretreatment serum prostate specific antigen levels. J. Urol. 1997;158:319–325
  2. Horwitz EM, Hanlon AL, Pinover WH, et al.  Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques. Cancer. 2001;92:1281–1287
  3. Horwitz EM, Vicini FA, Ziaja EL, et al.  Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control. Int. J. Radiat. Oncol. Biol. Phys. 1996;36:565–571
  4. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:1035–41
  5. Horwitz EM, Uzzo RG, Hanlon AL, et al.  Modifying the ASTRO definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3d conformal radiation therapy alone. J. Urol. 2003;169:2153–2159
  6. Zelefsky MJ, Fuks Z, Hunt M, et al.  High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J. Urol. 2001;166:876–881

☆ Sources of funding: Cancer Care Ontario and the Ontario Ministry for Health and Long-Term Care.

☆☆ For correspondence: M Brundage, Kingston Regional Cancer Centre, 25 King Street West, Kingston, Ont., Canada K7L 5P9.

★ Abstract provided by Bazian Ltd, London.

PII: S0305-7372(03)00100-2

doi: 10.1016/S0305-7372(03)00100-2

Cancer Treatment Reviews
Volume 29, Issue 3 , Pages 219-221 , June 2003

Article Tools